BCR/ABL is the first oncoprotein discovered in patients with CML and the first target for therapeutic intervention with small molecule tyrosine kinase inhibitors (TKIs) based drugs2. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.